Case
====

Topical minoxidil is widely utilized as an off-label therapy for alopecia areata in adults and children. We report here a case of generalized hypertrichosis in a 2 year old child.

The patient was a 2-year old hispanic boy with no other significant medical history, who was affected by patchy alopecia areata involving 40% of the scalp since the age of 1 year. Three months before the patient came to our clinic he was prescribed 5% minoxidil foam to be applied to affected areas of the scalp twice a day. After two months the parents noticed hair regrowth but also growth of long pigmented hairs on his face, trunk and limbs. The patient's mother admitted that she had possibly been applying more product than originally instructed.

Clinical examination showed patchy alopecia areata involving 10% of the scalp and generalized hypertrichosis ( [Figure 1](#f1){ref-type="fig"}). No other side effects were observed. The patient was referred to a pediatric endocrinologist who excluded underlying endocrinological abnormalities. Minoxidil was discontinued and considerable clinical improvement of the hypertrichosis and the scalp alopecia areata was observed at two month follow up.

![Note the augmented number and thickness of hairs in the back and face of this young child caracterizing hypertrichosis.](f1000research-2-2444-g0000){#f1}

Discussion
==========

Minoxidil affects hair growth through incompletely understood mechanisms; known effects include increased duration of the anagen growth phase, agonistic affects on adenosine-triphosphate (ATP)-sensitive potassium channels, and prostaglandin stimulation in the dermal papillae. It is clinically indicated as a therapy for androgenetic alopecia, however off-label uses include topical application in alopecia areata in both adults and children.

Systemic administration of minoxidil either by oral administration to the mother during pregnancy or by oral ingestion by the child, has led to rarely reported instances of diffuse hypertrichosis in children ^[@ref-1],\ [@ref-2]^ and newborns via maternal--fetal transmission ^[@ref-3],\ [@ref-4]^.

Hypertrichosis is a common side effect of topical minoxidil treatment in women. Although usually localized to the face, it may occasionally involve limbs and other body areas ^[@ref-5],\ [@ref-6]^. To our knowledge there are no reports of generalized hypertrichosis in a pediatric population.

Systemic absorption of the drug is typically minimal with topical therapy, with 1.4% of the applied dose being absorbed ^[@ref-7]^. However, hypotheses on the pathogenesis of the diffuse hypertrichosis reaction routinely include systemic absorption, as well as high sensitivity of the follicular apparatus to minoxidil ^[@ref-5]^. In our patient, the excessive dose (both in terms of concentration and daily quantity) in combination with the patient's low body weight favoured systemic adsorption. Further support for systemic effects are noted in the reported cardiovascular side affects in three patients from 10 to 14 years of age treated for alopecia areata with minoxidil 2% topically twice a day ^[@ref-8]^. These effects included sinus tachycardia, sensation of palpitation and dizziness.

Conclusion
==========

The efficacy of topical minoxidil in alopecia areata has never been definitively proven ^[@ref-9]^. The possibility of systemic absorption contraindicates, in our opinion, this treatment in young children, who can develop serious cutaneous or systemic side effects. Furthermore, there are some alternative treatments of alopecia areata in children that are considered safer, for example topical immunotherapy and topical anthraline application.
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This is a well-written and instructive case report. It emphasizes that minoxidil, which is not a standard first line therapy in alopecia areata, should probably not be used in young children because of possible side effects.

Some comments: Detailed information about the endocrinological work-up performed would be of interest.Were minoxidil levels in the blood of the child assessed?Was there a family history of hypertrichosis?Is there a follow up picture that shows the improvement of the hypertrichosis after discontinuation of minoxidil?
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This case report is well written and informative. Here are a few comments:

1\. \" *The patient was referred to a pediatric endocrinologist who excluded underlying endocrinological abnormalities*.\"

\- It would be very helpful if a short paragraph about the possible endocrinologic causes and the lab work done by the endocrinologist to exclude them could be added.

2\. \" *Minoxidil was discontinued and considerable clinical improvement of the hypertrichosis and the scalp alopecia areata  was observed at two month follow up*\"

\- Are there any photographs to demonstrate the improvement of hypertrichosis?
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